COX2 inhibitors can lower inflammatory factors, thereby modulating macrophage recruitment and activation of the anticancer immune milieu; restrict tumor angiogenesis by downregulating vascular endothelial growth factor; and promote tumor cell apoptosis by inhibiting the PI3K/Akt signaling pathway [34]. The gene discussed is VEGFA; the disease is neoplasm.